Alk-Abello ASCHIX:ALKBC 92 Peter Lynch Fair Value is kr145.00 as of Jul. 12, 2026, which is 100% below its 10-year median of 1.97. GuruFocus rates CHIX:ALKBC with a GF Score™ of 92/100 and a GF Value™ of kr208.02 (Modestly Overvalued). Among 67 Biotechnology companies, Alk-Abello AS ranks worse than 59.7% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, Alk-Abello AS's PEG is 1. Alk-Abello AS's 5-Year TTM EBITDA Growth Rate is 25.
Alk-Abello AS's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was kr5.80. Therefore, the Peter Lynch Fair Value for today is kr145.00.
As of today (2026-07-12), Alk-Abello AS's share price is kr256.30. Alk-Abello AS's Peter Lynch fair value is kr145.00. Therefore, Alk-Abello AS's Price to Peter Lynch Fair Value Ratio for today is 1.77.
The historical rank and industry rank for Alk-Abello AS's Peter Lynch Fair Value or its related term are showing as below:
CHIX:ALKBc'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.3 Med: 1.97 Max: 28.16
Current: 1.67
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of Alk-Abello AS was 28.16. The lowest was 1.30. And the median was 1.97.
CHIX:ALKBc's Price-to-Peter-Lynch-Fair-Value is ranked worse than 59.7% of 67
companies
in the Biotechnology industry
Industry Median: 1.2
vs CHIX:ALKBc: 1.67
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
Alk-Abello AS (CHIX:ALKBc) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 25 instead of 15 in this case.
Alk-Abello AS's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
256.30
/
145.00
=
1.77
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alk-Abello AS Peter Lynch Fair Value Related Terms
Alk-Abello AS Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALKBC vs VRTX, REGN, ALNY: Peter Lynch Fair Value Comparison
For the Biotechnology subindustry, Alk-Abello AS's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS Price-to-Peter-Lynch-Fair-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's Price-to-Peter-Lynch-Fair-Value falls into.
Alk-Abello AS's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr5.80.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of kr145.00 mean?
Alk-Abello AS (CHIX:ALKBC) has a Peter Lynch Fair Value of kr145.00 as of Jul. 12, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Alk-Abello AS and its competitors. This is 7260% above median its historical median of 1.97. Over the past decade, Alk-Abello AS's Peter Lynch Fair Value has ranged from 1.30 to 28.16. According to the industry distribution chart, Alk-Abello AS ranks #40 out of 67 companies in the Biotechnology industry, placing it in the top 59.7%.
Is Alk-Abello AS's Peter Lynch Fair Value too high?
Alk-Abello AS's current Peter Lynch Fair Value of kr145.00 is 7260% above median its 10-year median of 1.97. Over the past 10 years, this metric has ranged from a low of 1.30 to a high of 28.16. Based on the distribution chart, Alk-Abello AS ranks #40 out of 67 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alk-Abello AS has a GF Score™ of 92/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Peter Lynch Fair Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #40 out of 67 companies for Peter Lynch Fair Value. This places Alk-Abello AS in the lower half of its industry. The industry median Peter Lynch Fair Value is 1.20. Historically, Alk-Abello AS's own Peter Lynch Fair Value has ranged from 1.30 to 28.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Biotechnology company?
The median Peter Lynch Fair Value among Biotechnology companies is 1.20, based on 67 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on Alk-Abello AS and its competitors. For the Biotechnology industry, the median Peter Lynch Fair Value is 1.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current Peter Lynch Fair Value is kr145.00, which is 7260% above median its own 10-year median of 1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr208.02, compared to a current price of kr256.30 — trading 23.2% above its estimated fair value. The current Peter Lynch Fair Value is kr145.00, which is 7260% above median its 10-year median of 1.97. Alk-Abello AS's overall GF Score™ is 92/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current Peter Lynch Fair Value is kr145.00 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of kr256.30 is trading 23.2% above its estimated GF Value™ of kr208.02.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for CHIX:ALKBC:
Peter Lynch Fair Value: kr145.00 (7260% above median its 10-year median of 1.97)
GF Value™: kr208.02 vs. price of kr256.30 (23.2% above fair value)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
92GF Score
Get the complete analysis for CHIX:ALKBC
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
